Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORTC Melanoma Group

Next Previous
Search
Trial Profile

Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORTC Melanoma Group

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms EORTC 18071
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 01 Apr 2023 Results of post hoc pooled data from NCT00636168 and NCT02388906; assessing RFS and OS with nivolumab versus placebo and the numbers needed to treat (NNT) over 4 years, published in the Cancer Immunology Immunotherapy
  • 03 Dec 2021 Results of pooled analysis from (CheckMate-238 and EORTC 18071) assessing the impact of accounting for cured patients on the cost-effectiveness (CE) profile of nivolumab versus observation in adjuvant treatment of melanoma, presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
  • 15 Oct 2021 Results of pooled analysis of indirect treatment comparison (ITC) of adjuvant nivolumab versus placebo from CheckMate 238 and European Organisation for Research and Treatment of Cancer (EORTC) published in the European Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top